7 USD
-0.02 (-0.28%)
Taking everything into account, GYRE scores 6 out of 10 in our fundamental rating. GYRE was compared to 530 industry peers in the Biotechnology industry. GYRE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GYRE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
GYRE had positive earnings in the past year.
GYRE had a positive operating cash flow in the past year.
In the past 5 years GYRE reported 4 times negative net income.
In the past 5 years GYRE reported 4 times negative operating cash flow.
1.2 Ratios
GYRE's Return On Assets of 4.17% is amongst the best of the industry. GYRE outperforms 90.38% of its industry peers.
The Return On Equity of GYRE (6.53%) is better than 90.75% of its industry peers.
GYRE's Return On Invested Capital of 6.46% is amongst the best of the industry. GYRE outperforms 92.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.17% | ||
| ROE | 6.53% | ||
| ROIC | 6.46% |
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GYRE has a better Profit Margin (6.20%) than 90.19% of its industry peers.
GYRE has a Operating Margin of 11.22%. This is amongst the best in the industry. GYRE outperforms 91.89% of its industry peers.
Looking at the Gross Margin, with a value of 95.48%, GYRE belongs to the top of the industry, outperforming 95.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.22% | ||
| PM (TTM) | 6.2% | ||
| GM | 95.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GYRE is destroying value.
GYRE has more shares outstanding than it did 1 year ago.
GYRE has more shares outstanding than it did 5 years ago.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
GYRE has an Altman-Z score of 7.65. This indicates that GYRE is financially healthy and has little risk of bankruptcy at the moment.
GYRE's Altman-Z score of 7.65 is fine compared to the rest of the industry. GYRE outperforms 78.87% of its industry peers.
There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.65 |
ROIC/WACC0.74
WACC8.76%
2.3 Liquidity
GYRE has a Current Ratio of 6.19. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.19, GYRE is in the better half of the industry, outperforming 63.58% of the companies in the same industry.
GYRE has a Quick Ratio of 5.64. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
GYRE has a better Quick ratio (5.64) than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 128.26% over the past year.
GYRE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -43.94%.
GYRE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.34% yearly.
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%
3.2 Future
The Earnings Per Share is expected to grow by 16.75% on average over the next years. This is quite good.
Based on estimates for the next years, GYRE will show a quite strong growth in Revenue. The Revenue will grow by 17.78% on average per year.
EPS Next Y-51.43%
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
EPS Next 5Y16.75%
Revenue Next Year-3.9%
Revenue Next 2Y10.17%
Revenue Next 3Y6.86%
Revenue Next 5Y17.78%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 53.85 indicates a quite expensive valuation of GYRE.
90.57% of the companies in the same industry are more expensive than GYRE, based on the Price/Earnings ratio.
GYRE is valuated expensively when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 36.76, which means the current valuation is very expensive for GYRE.
91.51% of the companies in the same industry are more expensive than GYRE, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.35. GYRE is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.85 | ||
| Fwd PE | 36.76 |
4.2 Price Multiples
91.32% of the companies in the same industry are more expensive than GYRE, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, GYRE is valued cheaply inside the industry as 89.81% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 471.63 | ||
| EV/EBITDA | 38.92 |
4.3 Compensation for Growth
GYRE's earnings are expected to decrease with -39.03% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
5. Dividend
5.1 Amount
GYRE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:GYRE (12/31/2025, 10:16:06 AM)
7
-0.02 (-0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.44%
Inst Owner Change-9.21%
Ins Owners7.06%
Ins Owner Change0%
Market Cap636.23M
Revenue(TTM)107.27M
Net Income(TTM)6.65M
Analysts84.44
Price Target18.36 (162.29%)
Short Float %11.81%
Short Ratio19.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)194.08%
EPS beat(4)1
Avg EPS beat(4)13.67%
Min EPS beat(4)-102.82%
Max EPS beat(4)194.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.9%
Min Revenue beat(2)-14.79%
Max Revenue beat(2)-9.01%
Revenue beat(4)1
Avg Revenue beat(4)-7.84%
Min Revenue beat(4)-23.85%
Max Revenue beat(4)16.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.26%
EPS NQ rev (1m)6.66%
EPS NQ rev (3m)18.51%
EPS NY rev (1m)45.17%
EPS NY rev (3m)15.38%
Revenue NQ rev (1m)-2.59%
Revenue NQ rev (3m)-4.19%
Revenue NY rev (1m)-3.18%
Revenue NY rev (3m)-5.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.85 | ||
| Fwd PE | 36.76 | ||
| P/S | 5.93 | ||
| P/FCF | 471.63 | ||
| P/OCF | 164.1 | ||
| P/B | 6.24 | ||
| P/tB | 6.55 | ||
| EV/EBITDA | 38.92 |
EPS(TTM)0.13
EY1.86%
EPS(NY)0.19
Fwd EY2.72%
FCF(TTM)0.01
FCFY0.21%
OCF(TTM)0.04
OCFY0.61%
SpS1.18
BVpS1.12
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.81
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.17% | ||
| ROE | 6.53% | ||
| ROCE | 8.39% | ||
| ROIC | 6.46% | ||
| ROICexc | 11.19% | ||
| ROICexgc | 11.89% | ||
| OM | 11.22% | ||
| PM (TTM) | 6.2% | ||
| GM | 95.48% | ||
| FCFM | 1.26% |
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 110.59% | ||
| Cap/Sales | 2.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 27.08% | ||
| Profit Quality | 20.28% | ||
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.64 | ||
| Altman-Z | 7.65 |
F-Score5
WACC8.76%
ROIC/WACC0.74
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
EPS Next Y-51.43%
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
EPS Next 5Y16.75%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%
Revenue Next Year-3.9%
Revenue Next 2Y10.17%
Revenue Next 3Y6.86%
Revenue Next 5Y17.78%
EBIT growth 1Y-72.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.41%
EBIT Next 3Y-66.98%
EBIT Next 5YN/A
FCF growth 1Y110.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.93%
OCF growth 3YN/A
OCF growth 5YN/A
GYRE THERAPEUTICS INC / GYRE FAQ
What is the fundamental rating for GYRE stock?
ChartMill assigns a fundamental rating of 6 / 10 to GYRE.
What is the valuation status of GYRE THERAPEUTICS INC (GYRE) stock?
ChartMill assigns a valuation rating of 4 / 10 to GYRE THERAPEUTICS INC (GYRE). This can be considered as Fairly Valued.
Can you provide the profitability details for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) has a profitability rating of 5 / 10.
What are the PE and PB ratios of GYRE THERAPEUTICS INC (GYRE) stock?
The Price/Earnings (PE) ratio for GYRE THERAPEUTICS INC (GYRE) is 53.85 and the Price/Book (PB) ratio is 6.24.
What is the earnings growth outlook for GYRE THERAPEUTICS INC?
The Earnings per Share (EPS) of GYRE THERAPEUTICS INC (GYRE) is expected to decline by -51.43% in the next year.